Related Experiment Video
Updated: Apr 3, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation
Grace E Kim1, Jenna L Ross2, Chaoqin Xie3
1Department of Cellular and Molecular Physiology, Yale University, New Haven, CT 06520, USA.
Aims:
Liver kinase B1 (LKB1) is a protein kinase that activates the metabolic regulator AMP-activated protein kinase (AMPK) and other related kinases. Deletion of LKB1 in mice leads to cardiomyopathy and atrial fibrillation (AF). However, the specific role of the LKB1 pathway in early atrial biology remains unknown. Thus, we investigated whether LKB1 deletion altered atrial channel expression and electrophysiological function in a cardiomyocyte-specific knockout mouse model.
Methods And Results:
We performed a systematic comparison of αMHC-Cre LKB1(fl/fl) and littermate LKB1(fl/fl) male mice. This included analysis of gene expression, histology, and echocardiography, as well as cellular and tissue-level electrophysiology using patch-clamp recordings in vitro, optical mapping ex vivo, and ECG recordings in vivo. At postnatal day 1, atrial depolarization was prolonged, and Nav1.5 and Cx40 expression were markedly down-regulated in MHC-Cre LKB1(fl/fl) mice. Inward sodium current density was significantly decreased in MHC-Cre LKB1(fl/fl) neonatal atrial myocytes. Subsequently, additional alterations in atrial channel expression, atrial fibrosis, and spontaneous onset of AF developed by 2 weeks of age. In adult mice, abnormalities of interatrial conduction and bi-atrial electrical coupling were observed, likely promoting the perpetuation of AF. Mice with AMPK-inactivated hearts demonstrated modest overlap in channel expression with MHC-Cre LKB1(fl/fl) hearts, but retained normal structure, electrophysiological function and contractility.
Conclusions:
Deletion of LKB1 causes early defects in atrial channel expression, action potential generation and conduction, which precede widespread atrial remodelling, fibrosis and AF. LKB1 is critical for normal atrial growth and electrophysiological function.
Insights
Liver kinase B1 (LKB1) deletion in mice causes early atrial electrical defects, impacting channel expression and conduction before fibrosis and atrial fibrillation (AF) develop. LKB1 is crucial for normal atrial development and function.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Electrophysiology
Background:
- Liver kinase B1 (LKB1) is a key kinase activating AMP-activated protein kinase (AMPK).
- LKB1 deficiency in mice results in cardiomyopathy and atrial fibrillation (AF).
- The role of LKB1 in early atrial development and electrophysiology is not well understood.
Purpose of the Study:
- To investigate the impact of cardiomyocyte-specific LKB1 deletion on atrial channel expression.
- To determine the effects of LKB1 deletion on atrial electrophysiological function in a mouse model.
- To elucidate the role of LKB1 in early atrial biology.
Main Methods:
- Utilized a cardiomyocyte-specific LKB1 knockout mouse model (αMHC-Cre LKB1(fl/fl)).
- Conducted gene expression analysis, histology, and echocardiography.
- Performed in vitro patch-clamp, ex vivo optical mapping, and in vivo ECG recordings.
Main Results:
- Early defects in atrial depolarization, Nav1.5, and Cx40 expression were observed in LKB1-deficient neonatal mice.
- Reduced inward sodium current density in neonatal atrial myocytes.
- Development of atrial fibrosis, AF, and impaired interatrial conduction by adulthood.
Conclusions:
- LKB1 deletion leads to early atrial channel and electrophysiological defects.
- These defects precede atrial remodeling, fibrosis, and AF onset.
- LKB1 is essential for normal atrial growth and electrophysiological integrity.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Mechanism of Cardiac Arrhythmias
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

